Navigation Links
Nanoparticle-based battlefield pain treatment moves a step closer
Date:9/24/2009

Ann Arbor, Mich. University of Michigan scientists have developed a combination drug that promises a safer, more precise way for medics and fellow soldiers in battle situations to give a fallen soldier both morphine and a drug that limits morphine's dangerous side effects.

They use nanotechnology to devise ultra-small polymer particles capable of carrying the drugs into the body. The development of the combination drug makes possible a precise feedback system that can safely regulate release of the drugs aboard the nanoparticles.

The scientists at the Michigan Nanotechnology Institute for Medicine and Biological Sciences report their results in the September issue of Bioorganic & Medicinal Chemistry Letters.

Context

Soldiers injured in combat typically receive morphine as soon as possible to relieve pain. Morphine, however, also depresses normal breathing and blood pressure, sometimes to life-threatening levels. So medics need to give a short-acting drug that aids normal respiration and heart beat, but in doses that still allow the morphine to relieve pain effectively. Today, achieving that balance is a challenge outside a hospital.

The combination drug that U-M scientists have developed promises to make balanced treatment possible even in combat zones, says James R. Baker, Jr., M.D., director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS) and the study's senior author.

"This system could improve pain management for millions of patients with chronic illnesses," says Baker, Ruth Dow Doan Professor and allergy division chief in the U-M Department of Internal Medicine.

The long-range goal of the research, funded by the U.S. Defense Advanced Research Projects Agency, is to develop a practical method that medics or soldiers themselves could administer, perhaps using an auto-injector device.

Research details

U-M chemists screened several compounds to search for a successful "pro drug," a drug that can release or become another drug. In this case, they wanted one that could convert to Naloxone, a drug now used to counter morphine's effects, but would activate only when blood oxygen levels drop too low. In laboratory tests using human plasma, one pro drug successfully sensed oxygen levels and turned on or off as needed.

"When respiratory distress is too severe, that will trigger release of Naloxone, the antagonist (morphine-suppressing) drug. When the oxygen blood levels go up, that will stop the action of the antagonist drug and more morphine will be available," says Baohua Huang, Ph.D., the study's first author and a research investigator at the Michigan Nanotechnology Institute and in Internal Medicine.

What's next

MNIMBS scientists are proceeding with animal studies of the pro drug's effects and will develop a dendrimer that can carry the pro drug and morphine, using a dendrimer platform technology previously developed at U-M. They hope to advance to more animal and eventually human studies.


'/>"/>

Contact: Anne Rueter
arueter@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related biology news :

1. Trial of new treatment for advanced melanoma shows rapid shrinking of tumors
2. Rethinking Alzheimers disease and its treatment targets
3. Diabetes drug kills cancer stem cells in combination treatment in mice
4. UCF discovery could open door to obesity, diabetes treatments
5. Mothers immune system may block fetal treatments for blood diseases
6. Protein handlers should be effective treatment target for cancer and Alzheimers
7. Experimental treatment halts hypoxic-ischemic brain injury in newborns
8. Discovery to aid in future treatments of third-world parasites
9. ISU researchers find possible treatment for spinal muscular atrophy
10. Promising new treatment for Alzheimers suggested based on Hebrew University research
11. New technique can fast-track better ionic liquids for biomass pre-treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... WuXi AppTec, a leading global pharmaceutical, ... platform company, today announced that its Lab Testing ... once again passed US FDA,s bioequivalence (BE) ... inspectors from FDA thoroughly audited WuXi,s quality system ... integrity, operation infrastructure, equipment, sample storage, archival system, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ACEA Biosciences, a pioneer ... chronic diseases, has announced Dr. Roger (Feng) Luo as the new Vice President of ... a number of multinational drug companies, Dr. Luo will now team with Dr. Li ...
(Date:2/28/2017)... , Feb. 28, 2017 AMO Pharma Limited ... debilitating diseases including rare genetic diseases with limited or ... with the National Organization for Rare Diseases (NORD) and ... world in commemorating Rare Disease Day, the annual observance ... the millions of patients and families affected by rare ...
Breaking Biology Technology: